Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma
Conclusions: Diabetic patients who do not use metformin appear to be at higher risk of cancer-specific and any-cause mortality than patients without DM. It remains unclear, whether the severity of DM in this group of patients or the use of metformin itself affects outcomes of UCB. The mechanisms behind the effect of DM on patients with UCB and the potential protective effect of metformin need further elucidation.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Malte Rieken, Evanguelos Xylinas, Luis Kluth, Joseph J. Crivelli, James Chrystal, Talia Faison, Yair Lotan, Pierre I. Karakiewicz, Maxine Sun, Harun Fajkovic, Marek Babjuk, Alexander Bachmann, Douglas S. Scherr, Shahrokh F. Shariat Tags: Abstracts for Online Original Articles and Reviews Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Diabetes | Diabetes Mellitus | Endocrinology | Fortamet | Metformin | Neoadjuvant Therapy | Urology & Nephrology